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An Interagency Panel Session organized by the NASA Human Research Program Space Radiation 
Program Element (SRPE) was held during the NASA Human Research Program (HRP) 
Investigator’s Workshop (IWS) in Galveston, Texas on January 26, 2017 to identify 
complementary research areas that will advance the testing and development of medical 
countermeasures (MCM) in support of radioprotection and radiation mitigation on the ground 
and in space.  There were several areas of common interest identified among the various 
participating agencies.  This report provides a summary of the topics discussed by each agency 
along with potential areas of intersection for mutual collaboration opportunities.  Common 
goals included repurposing of pharmaceuticals, neutraceuticals for use as radioprotectors 
and/or mitigators, low-dose/chronic exposure paradigms, late effects post-radiation exposure, 
mixed-field exposures of gamma-neutron, performance decrements, and methods to 
determine individual exposure levels. 
Introduction 
NASA has been charged with preparing for the next frontier of exploration missions that will 
include sending astronauts to cis-lunar habitats, the moon and Mars over the next 30 years.  
This requires NASA to understand the implications to the astronauts’ health with radiation 
being one of the greater unknowns.  The International Space Station (ISS) has provided key 
evidence on the impact microgravity and living in space has on the human body; however, 
radiation exposures accumulated on the ISS is a fraction of what the astronauts will experience 
during longer, deep space missions.  While shielding on spacecraft and in the habitats will 
provide some mitigation, it is impossible to prevent astronauts from being exposed to high-
energy, low dose-rates of radiation.  To address the impact of radiation-induced health 
questions, NASA recently upgraded its Galactic Cosmic Ray (GCR) Simulator at the NASA Space 
Radiation Laboratory (NSRL) to provide a more accurate representation of the space radiation 
environment to support ground based research.  This facility will be critical to support 
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evaluation of medical countermeasures to protect or mitigate astronauts from GCR exposures.  
NASA has developed requirements and a plan to pursue medical countermeasures to provide 
mitigation and reduce the overall radiation risk to astronauts.  One aspect of NASA’s plan is to 
engage with interagency partners to leverage their existing research and development, to learn 
from them, and potentially expedite NASA’s goals.  In order to accomplish this, it is necessary to 
understand the goals of each agency and identify common areas where collaborations can 
occur.  This prompted the joint session organized by NASA SRPE during the NASA HRP 
Investigator’s Workshop.  The Interagency Panel Session was organized to address specific 
questions regarding radiation-induced health effects, exposure concerns, and MCM research 
and development of interest to each participating Agency.  It included presentations from the 
National Institute of Health (NIH)/National Cancer Institute (NCI), NIH/National Institute for 
Allergy and Infectious Disease (NIAID), NIH/National Heart Lung and Blood Institute (NHLBI), 
Biomedical Advanced Research and Development Authority (BARDA) and the Defense Threat 
Reduction Agency (DTRA), with attendance by the Armed Forces Radiobiology Research 
Institute (AFRRI).  A highlight of each Agency’s key areas of interest is illustrated in Figure 1.  
Figure 1. Agency areas of interest and the intersection with NASA. 
Each Agency has unique requirements for MCM development and implementation.  NASA SRPE 
has four primary risk areas, Acute Radiation Syndrome, Cancer, Degenerative Tissue Effects and 
Central Nervous System, each with multiple endpoints that overlap with the various Agencies in 
different areas.   
Radioprotectors and radiomitigators have been in the spotlight for more than a decade post-
9/11 era.  The potential for a nuclear accident or worse, detonation, increased significantly and 
several efforts were born to develop ways to protect the public and military warfighter 
including, the National Institute of Health (NIH) National Institute for Allergy and Infectious 
Diseases (NIAID) Radiation Nuclear Countermeasures Program (RNCP), and the Biomedical 
Advanced Research and Development Authority (BARDA).  Their efforts have focused on the 
development of end-to-end solutions to respond to mass injuries associated with nuclear and 
radiological incidents.  The primary goal has been rescuing victims from acute radiation 
exposures that may result in loss of life.  Several agents have been developed, FDA approved 
and stockpiled in a relatively short period to address these needs and many more are in the 
pipeline as potential candidates to include in the Strategic National Stockpile (SNS).  The 
military has its concerns for the warfighter during these events and other activities that may 
expose troops to radiation.  The possibility of performance decrements exists if troops are 
exposed to even low doses of radiation during missions or support efforts that may result in 
mission compromise.  However, the negative effects of radiation exposure extend far beyond 
the potential for a nuclear disaster.  Millions of people are treated annually with radiotherapy 
and suffer from latent effects that disrupt their overall quality of life.  The Radiation Research 
Program, Division of Cancer Treatment and Diagnosis under the NIH National Cancer Institute 
(NCI) is chartered with protecting normal tissue during radiation therapy and mitigating the 
radiation induced side effects  Latent effects from radiation exposure involve the vascular 
system to a great extent, which can compromise multiple organs in the body.  The NIH National 
Heart Lung and Blood Institute (NHLBI) is interested in learning what can be done to mitigate 
these effects post-radiotherapy.  The health effects being addressed terrestrially have benefit 
to NASA to address potential in-flight and latent effects anticipated post-long duration, deep 
exploration missions.   
National Institute of Health/National Cancer Institute (NIH/NCI) 
Dr. Pataje Prasanna, Radiation Research Program, Division of Cancer Treatment and Diagnosis 
under NIH/NCI, gave an overview of “Radioprotectors and Mitigators for Improving 
Radiotherapy”.  Radiotherapy is currently used to treat half of all cancer patients and has 
become a curative modality.  In 2012, there were 14.1M new cancer cases and 7M were 
treated with radiotherapy.  Projections for future cancer cases are staggering.  By 2030 it is 
estimated there will be 24.6M new cancer cases and 12M of those will be treated using 
radiotherapy.1  A focus for NCI is how to address post-treatment quality of life.  Radiotherapy 
has been shown to reduce cognitive function anywhere from 50-90% in cancer patients being 
treated for glioblastoma, and head and neck cancers.  Radiation-induced brain injury involves 
inflammation, changes in the central nervous system (CNS) microenvironment, signaling 
dysfunction, vascular damage, and injury to neurons, cellular organelles, demyelination, and 
collagen deposition.  It was noted that apoptosis and necrosis appear to play a major role as 
well.  Development of radioprotectors will allow for dose escalation with the goal of eliminating 
the tumor while a radiation mitigator will help improve post-treatment quality of life. Figure 2 
depicts the pathway for the translation of radiation effect modulators to the radiation oncology 
clinic.2-4 The process involves moving the work through a logical hierarchy of model systems 
from in vitro based assays through in vivo tumor models and ultimately to the clinic.  Early 
screening using in vitro systems could save resources and time.  
 
Department of Defense/Defense Threat Reduction Agency (DOD/DTRA) 
The Defense Threat Reduction Agency (DTRA) has two primary objectives 1) to develop 
prophylaxes to prevent latent effects associated with radiation exposure that occurs during 
warfighter operations and 2) to develop environmental monitoring solutions for near- to mid-
field characterization of nuclear activity.  DTRA’s approach for developing prophylaxes is to 
study intracellular response-recovery modes for different domains of life, with a focus on 
understanding intrinsic radioresistance.  Environmental monitoring surveillance approaches use 
omics, genotypic, functional and phenotype changes related to exposure.  Additional work in 
this area explores development of materials with multicatalytic centers for successive analyte 
Figure 2.  Workflow for development of radioprotectors and mitigators for radiation oncology (Prasanna et. al. 
2015). 
characterization which increase signal veracity.   Studies are designed to develop motifs which 
can be incorporated into standard optical or electrochemical platforms.  Other topics explore 
changes to local flora and fauna in the surrounding environment that are relatable to exposure 
of distinct chemical species or level/type/quality of radiation.  The demographics, low-
dose/low-dose rate and mixed neutron/gamma radiation field are complementary to NASA’s 
interests.  DTRA is also concerned with performance decrements for the warfighter which 
complements NASA’s interest related to in-flight events that may occur with astronauts on 
long-duration missions.   
National Institute of Health/National Institute of Allergy and Infectious Disease (NIAID) 
NIAID Program Officers, Drs. Carmen Rios and Lanyn Taliaferro, provided background 
information on the Radiation Nuclear Countermeasures Program.  In 2004, NIAID was directed 
by the Department of Health and Human Services (HHS) to start a research program to 
accelerate development of radiation/nuclear medical countermeasures (MCMs) for the 
Strategic National Stockpile.  Their primary mission is to support early to mid-stage research to 
develop radiation/nuclear MCMs and biodosimetry tools with an emphasis on three key areas 
1) drugs to treat or mitigate radiation injury 24 hours post-exposure, 2) drugs to remove 
radioactive materials from the body and 3) biodosimetry tools  
Figure 3. NIAIDs portfolio includes the evaluation of numerous MCM candidates and biodosimetry 
technologies. 
and biomarker identification to determine levels of radiation exposure.  This is accomplished 
through grants, collaborative agreements, contracts, and inter- and intra-agency agreements.  
Over 200 MCM candidates and biomarkers have been evaluated (Figure 3).  Of these, six 
biodosimetry approaches which have reached higher technology readiness levels (TRL) have 
transitioned to BARDA for advanced development, and two MCMs are in the DOD pipeline for 
prophylaxis development.  NIAID’s efforts resulted in the first two MCMs, Neupogen® and 
Neulasta®, approved by the FDA under the Animal Rule with the indication to treat 
Hematopoietic Acute Radiation Syndrome (H-ARS).5  NIAID also received an FDA Investigational 
New Drug authorization to proceed with first-in-human safety/PK evaluation of an oral 
radionuclide decorporation agent (Hydroxypyridinone – 3,4,3(1,2 - HOPO)).  Delayed effects 
from acute radiation exposure (DEARE) is another area of interest in NIAID’s portfolio.  DEARE 
along with H-ARS mitigators are areas of common interest between NASA and NIAID.  NASA is 
concerned with protecting astronauts from acute exposures caused by solar particle events and 
mitigating any delayed effects from these exposures that could impact quality of life for crew 
upon returning to Earth.   
Assistant Secretary for Preparedness and Response/Biomedical Advanced Research and 
Development Authority (ASPR/BARDA) 
Dr. Mary Homer, BARDA, gave a talk on their “Radiological and Nuclear Countermeasure 
Program”, addressing areas of focus for preparedness in order to treat injury due to exposure 
of acute ionizing radiation caused by Improvised Nuclear Device (IND) or Radiological Dispersal 
Device (RDD) Events with priority given to IND-related injuries since the impact is predicted to 
be greater.  BARDA focuses on MCM candidates that are ready for advanced development.   
Due to the complex 
spectrum of injuries 
that are anticipated to 
include combined 
injuries of acute 
radiation exposure, 
trauma, and thermal 
burn, treatment is 
expected to require a 
polypharmacy 
approach.  Over the 
years, BARDA has 
evolved its focus away 
from organ-centric 
syndromes to focus on 
more 
pathophysiological 
processes involved in 
Ischemia 
Vascular Injury / 
Sepsis 
Coagulopathy/ 
Fibrinolysis 
Inflammation 
Cell Death  
Figure 4. The five main focus areas for targeted product development include 
radiation injury.  The five main focus areas for targeted product development include:  vascular 
injury, coagulopathies, inflammation, cell death, and ischemia.6  For the near term, the primary 
MCM development areas are for treatment of hematopoietic injury, specifically targeting 
thrombocytopenia and vascular injury.  NASA and BARDA are both interested in addressing the 
systemic pathophysiological processes, along with combined effects of high skin exposures and 
the impact to the blood forming organs.   
Dr. Lynne Wathen, BARDA, gave a brief overview on the development of radiation biodosimetry 
tests that may be useful during space missions or a mass casualty incidents on earth. 
Biodosimetry is the measurement of the biological response to an absorbed dose of ionizing 
radiation and offers an added clinical benefit to patient observation for post-irradiation 
symptoms by estimating qualitative and quantitative absorbed ionizing radiation dose. A point-
of-care (POC), immediate qualitative test can deliver dose prediction to triage low- and no-
absorption victims from all others. In addition, a quantitative dose absorption test delivered 
quickly can inform physicians in advance of diagnostic neutropenia and the onset of acute 
radiation syndrome (ARS). Further, it can substitute a less efficient empirical treatment regimen 
with better-informed therapeutic management and consequently better allocation of scarce 
medical countermeasure resources. These two types of tests are currently under development 
with support from the United States Department of Health and Human Services (HHS). Initial 
assessments of test accuracy and positive/negative predictive values over a range of 0 to 10 
Gray (Gy) are underway using extensive clinical and non-clinical validation studies.   
National Institute of Health/National Heart Lung and Blood Institute (NHLBI) 
Dr. Keith Hoots, NHLBI, gave a presentation on vascular injury and the pathogenesis of 
endothelial injury.  Chronic radiation exposure and its effect on the vascular cell repair 
machinery was a focus area along with determining if there is an impact of low, chronic 
radiation exposure due to cross-talk between the endothelium and circulating inflammatory 
cells.  Another area of common interest includes the central nervous system (CNS) implications 
for chronic low-dose radiation exposure since key endothelial cell regulatory receptor activation 
appears to be relevant to inflammatory signaling across the blood-brain barrier.  Long-term 
radiation exposure and the impact on long non-coding RNAs in the vascular endothelium and 
other human cells was a key topic discussed.  NASA and NHLBI share areas of research interest 
in understanding the effect of chronic low-dose radiation on the vascular system along with the 
mechanisms underlying the impact and the relationship of these events to the CNS.   
National Aeronautics and Space Administration (NASA) 
NASA representative, Dr. Lisa Carnell, gave an overview of the risks from exposure to Space 
Radiation that may require physical and/or medical countermeasures.  There are two different 
problems to consider on long-duration deep space missions, solar particle events and galactic 
cosmic radiation.  Each needs to be addressed individually.  In the case of solar particle events, 
there is the potential for prodromal and H-ARS effects.  Mitigation strategies include: (1) storm 
shelters with active dosimetry; 
(2) space weather forecasting 
and operations scheduling that 
reduce exposure during 
extravehicular activities and 
provide notification for crew to 
shelter; and (3) MCMs that 
may include treatments for 
nausea and vomiting along 
with G-CSF for H-ARS, 
depending on the mission 
scenario (Table 1).   
Galactic cosmic radiation is comprised of approximately 86% protons (hydrogen nuclei), 13% 
helium nuclei, with 1% being the nuclei of heavier elements, called HZE ions.7  GCR is an even 
greater challenge to address because there are multiple effects to consider including risk of 
central nervous systems disorders, degenerative tissue effects in flight, and late effects that 
may include the central nervous system, cardiovascular and other degenerative tissue effects 
along with solid and hematological cancers.  An ideal MCM will provide cross risk mitigation by 
targeting common pathways for each health impact.  Table 2 provides a definition of an ideal 
MCM to address GCR.  Requirements for a MCM to be used will depend on the mission  
 scenario. A key aspect for consideration 
by NASA on long-duration missions is 
storage and shelf-life. A lyophilized form 
of a MCM may provide  longer stability 
and weight savings.  NASA has several 
areas of complementary interests with 
each of the Agencies identified beyond 
what was highlighted already.  NASA 
has a demographic aligned with DOD 
since the astronaut corps is highly 
trained and monitored similar to the 
military, while many of the other 
Agencies are addressing the general 
population.  There is a common need 
for extended shelf-life and storage for 
NASA and BARDA due to the need to 
include MCMs in the SNS.  Determining the exposure dose is of concern to all Agencies as is 
developing computational modeling scenarios to predict the risk of exposure resulting in 
adverse health effects to the public and astronauts. 
 
Table 1. Solar Particle Event  
Indications and Possible Treatment Options 
Symptom MCM Recommendation 
Nausea/Vomiting Ondansetron (Zofran®), Granisetron (Kytril®), 
Aprepitant (Emend®), Dexamethasone 
(Decadron®) 
Diarrhea Immodium® 
Dehydration Intravenous (IV) normal saline 
Infections penicillins, cephalosporins, macrolides, 
ciprofloxacin 
Respiratory prednisone 
Hematopoietic G-CSF, GM-CSF 
Burns Silver sulfadiazine, sterile gauze, parenteral 
opioid analgesics, crystalloid solutions, 
corticosteroid cream 
Table 2. Medical Countermeasure Criteria for GCR 
Radioprotection/Mitigation 
• Medical products and regimens that prevent and/or mitigate adverse 
health effects due to space radiation with emphasis on broad activity (i.e. 
multi-tissue) 
• Mechanism of action well known 
• Independent of sex 
• Capable of being delivered chronically for the period of the mission 
(potentially up to 3 years) 
• Easily administered; capable of self-administration (e.g. Oral, inhaled) 
• No contraindications with other drugs used for treating other symptoms 
or diseases during the mission 
• Known/potential benefits greater than known potential risks; minimal 
adverse events 
• Long shelf-life 
In Summary 
Several Federal Agencies including NIH/NIAID, NIH/NCI, DoD/DTRA, DoD/AFRRI, NIH/NHLBI and 
ASPR/BARDA have been studying, testing and developing medical countermeasures in support 
of anti-terrorism activities that may involve weapons of mass destruction, dirty bombs or other 
means of radiation exposure.  The exposures studied are typically acute, high doses of radiation 
including both gamma and neutrons.  In moving forward with Interagency collaborations, it is 
important to appreciate and understand that each Agency has unique requirements for medical 
countermeasures. Determining complementary research interests will help expedite research 
and maximize cost savings.   
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